rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AZN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out

      Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.

      8h agoSeeking AlphaAZNRYTMLLY
      Tempus AI and AstraZeneca amend agreement with new five-year, $200 million commitment
      13h agoInvesting.comAZNTEM
      The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
      16h agoYahoo FinanceAZNFRAFETNLIN
      AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
      Nov 17Yahoo FinanceAZN
      AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
      Nov 16ReutersAZN
      AstraZeneca Bet $2 Billion on Summit’s Cancer Drug. The FDA Just Said Not Yet.

      Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.

      Nov 16Barron'sAZNSMMT
      AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports By Reuters
      Nov 16Investing.comAZN
      AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe
      Nov 16BenzingaAZN
      AstraZeneca Wins Approvals for Generalized Myasthenia Gravis Drug Klygefa in US, EU

      AstraZeneca (AZN.L, AZN.ST) secured regulatory approvals in the US and the European Union for its ge

      Nov 16Yahoo FinanceAZN
      AstraZeneca’s Baxfendy Recommended for EU Approval Following Phase III Hypertension Trials

      AstraZeneca (LSE:AZN) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Baxfendy (baxdrostat), a treatment for adults with hypertension that remains inadequately controlled despite taking at least two blood pressure medications. The recommendation follows results from two Phase III clinical trials demonstrating statistically significant reductions in systolic blood pressure among patients with uncontrolled or res

      Nov 16Yahoo FinanceAZN
      AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
      Nov 16ReutersAZN
      AstraZeneca gets U.S. approval for two drugs
      Nov 16Investing.comAZN
      Is AstraZeneca (LSE:AZN) Reasonable After Its Oncology Led Cash Flow Push?
      Nov 14Yahoo FinanceAZN
      AstraZeneca (LSE:AZN) Will Transfer Its Primary Listing To The NYSE In 2026
      Nov 14Yahoo FinanceAZN
      AstraZeneca announces EMA’s CHMP recommends approval of Baxfendy
      Nov 13Yahoo FinanceAZN
      AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports By Reuters
      Nov 13Investing.comAZN
      AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
      Nov 13ReutersAZN
      AstraZeneca Reportedly Eliminates 600 US Sales Positions To Fund Pipeline
      Nov 13Yahoo FinanceAZN
      AstraZeneca cuts 600 US jobs amid $1.5B cost-saving overhaul - Bloomberg
      Nov 13Investing.comAZN
      AstraZeneca Cuts 600 US Sales Staff as Savings Drive Kicks In
      Nov 13BloombergAZN
      Oncology Market to Reach USD 732.45 Billion by 2035 as Merck, AstraZeneca, Roche, J&J and GSK Spend Billions on Deals to Beat the Patent Cliff
      Nov 13Yahoo FinanceAZNMRK
      EU panel backs AstraZeneca hypertension drug baxdrostat
      Nov 13ReutersAZN
      Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead and AstraZeneca ...

      Compugen Ltd (CGEN) posted $3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds $117.5 million in cash to fund operations into 2029.

      Nov 12Yahoo FinanceAZNCGENGILD
      AstraZeneca acquires bacterial vaccine biotech, Omniose
      Nov 11Yahoo FinanceAZN
      AstraZeneca’s Oncology Growth Is Outrunning The Farxiga Decline (NYSE:AZN)
      Nov 11Seeking AlphaAZN
      AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
      Nov 11Yahoo FinanceAZN
      AstraZeneca’s Reported $10 Billion Rhythm Bid Raises the Stakes for Palatin’s Obesity Pipeline (NASDAQ: P
      Nov 11BenzingaAZNPTN
      AstraZeneca (LSE:AZN) Reaffirms Guidance As Pipeline Strength Keeps Undervaluation In View
      Nov 10Yahoo FinanceAZN
      AstraZeneca (LSE:AZN) Stock Fair Value Edges Higher After Mixed Analyst Target Changes
      Nov 10Yahoo FinanceAZN
      AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
      Nov 10Yahoo FinanceAZN
      AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition
      Nov 10ReutersAZN
      AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say By Reuters
      Nov 4Investing.comAZN
      Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

      Rhythm specializes in treatments for metabolic conditions and severe obesity.

      Nov 4WSJAZNRYTM
      RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report
      Nov 4Yahoo FinanceAZN
      Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report

      Investing.com -- Rhythm Pharmaceuticals (NASDAQ) shares surged 28% on Wednesday after The Wall Street Journal reported that AstraZeneca (NASDAQ) had made a $10 billion acquisition offer for the biotech company.

      Nov 4Yahoo FinanceAZN
      AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say

      By Sabrina Valle, Milana Vinn and Amy-Jo Crowley Nov 4 (Reuters) - AstraZeneca made an offer of about $10 billion to acquire obesity drugmaker Rhythm Pharmaceuticals, according to three people

      Nov 4Yahoo FinanceAZN
      AstraZeneca (LSE:AZN) Filing Acceptance In Europe And Japan Puts Lung Cancer Combo Forward
      Nov 4Yahoo FinanceAZN
      AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing
      Nov 2BenzingaAZN
      Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
      Nov 2Yahoo FinanceALNYAZNREGN
      RBC Capital raises AstraZeneca stock price target on strong results
      Nov 2Investing.comAZN
      SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
      Nov 2Yahoo FinanceAZNMRK
      AstraZeneca: 3 Key Takeaways for Long-Term Investors
      Nov 1Yahoo FinanceAZN
      AstraZeneca Q3 2026 slides: oncology drives beat, deep pipeline fuels growth
      Nov 1Investing.comAZN
      Earnings call transcript: AstraZeneca beats Q3 2026 estimates, shares rise 7%
      Nov 1Investing.comAZN
      AstraZeneca (AZN) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 31The Globe and MailAZN
      AstraZeneca PLC (AZN) (Q3 2026) Earnings Call Highlights: Oncology Surges Past $21 Billion as ...
      Oct 30Yahoo FinanceAZN
      COVID Vaccine Giant AstraZeneca Stock Jumps 7%. What's Behind It?
      Oct 30Yahoo FinanceAZN
      Learn Why The Bull Case For AstraZeneca Stock Could Change Following Earnings Beat
      Oct 30Yahoo FinanceAZN
      AstraZeneca cans late-stage Ultomiris trial on lacklustre efficacy predictions
      Oct 30Yahoo FinanceAZN
      British Equities End Week in Green; AstraZeneca Jumps Post-Q3 Results

      The UK's FTSE 100 index closed the trading week 0.13% higher amid earnings releases from several cor

      Oct 30Yahoo FinanceAZN

      This is the newest page. Registered accounts read further back.